Immunopharmacology Comments

IL-1β in cardiovascular disease: Canakinumab was the first anti-inflammatory agent to exhibit efficacy as a treatment for atherosclerosis. Results from the CANTOS trial (NCT01327846) showed that canakinumab (in high-risk patients; in addition to standard-of-care therapy) reduced the number of recurrent cardiovascular events that were recorded at 3-4 years follow-up [5-6]. These results confirmed that disruption of the IL-1β inflammatory pathway was a valid therapeutic modality for cadiovascular disease prevention. It is informative to note that the largest reduction in cardiovascular mortality was observed in those patients who achieved the greatest reduction in the circulating inflammatory mediators IL-6 and CRP, which points to the importance of employing informed patient stratification in future studies.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Muckle-Wells syndrome	OMIM: 191900 Orphanet: ORPHA575	An anti-IL-1β therapeutic approved for Muckle-Wells syndrome.
Juvenile idiopathic arthritis- systemic	OMIM: 604302	An anti-IL-1β therapeutic approved for sJIA.	7
Familial cold autoinflammatory syndrome 1; FCAS1	OMIM: 120100 Orphanet: ORPHA47045	An anti-IL-1β therapeutic approved for FCAS1.	4